In 2015, Zhao et al. [16] reported the key role of the ZIP transporter, specifically isoform 12 (ZIP12), as a possible therapeutic target to mitigate the development of hypoxia-induced pulmonary hypertension induced by hypobaric hypoxia exposure (4500 m, 12% O2). This evidence concerns the gene SLC39A12 and pulmonary arterial hypertension.